Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

被引：71

作者：

Bayry, J

Lacroix-Desmazes, S

Kazatchkine, MD

Kaveri, SV ^{[1
]}

机构：

[1] INSERM, U430, 15 Rue Ecole Med, F-75006 Paris, France

[2] Univ Paris 06, Inst Cordeliers, F-75006 Paris, France

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2004年 / 25卷 / 06期

关键词：

D O I：

10.1016/j.tips.2004.04.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, Wig provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.

引用

收藏

页码：306 / 310

页数：5

相关论文

共 40 条

[1] Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections [J].

Barekzi, NA ;

Felts, AG ;

Poelstra, KA ;

Slunt, JB ;

Grainger, DW .

PHARMACEUTICAL RESEARCH, 2002, 19 (12) :1801-1807

[2] Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence [J].

Barsoum, NR ;

Bunnapradist, S ;

Mougdil, A ;

Toyoda, M ;

Vo, A ;

Jordan, SC .

AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (05) :425-428

[3] Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice [J].

Ben-Nathan, D ;

Lustig, S ;

Tam, G ;

Robinzon, S ;

Segal, S ;

Rager-Zisman, B .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01) :5-12

[4] Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1 [J].

Bouhlal, H ;

Hocini, H ;

Quillent-Grégoire, C ;

Donkova, V ;

Rose, S ;

Amara, A ;

Longhi, R ;

Haeffner-Cavaillon, N ;

Beretta, A ;

Kaveri, SV ;

Kazatchkine, MD .

JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7606-7611

[5] Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency [J].

Busse, PJ ;

Razvi, S ;

Cunningham-Rundles, C .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (06) :1001-1004

[6]

Coste S, 2002, REV NEUROL-FRANCE, V158, P361

[7] Intravenous immune globulin therapy for neurologic diseases [J].

Dalakas, MC .

ANNALS OF INTERNAL MEDICINE, 1997, 126 (09) :721-730

[8] Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome:: A European randomized, double-blind, placebo-controlled trial [J].

Darenberg, J ;

Ihendyane, N ;

Sjölin, J ;

Aufwerber, E ;

Haidl, S ;

Follin, P ;

Andersson, J ;

Norrby-Teglund, A .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :333-340

[9] Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model [J].

De Hennezel, L ;

Ramisse, F ;

Binder, P ;

Marchal, G ;

Alonso, JM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :316-318

[10] Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins [J].

Douzinas, EE ;

Pitaridis, MT ;

Louris, G ;

Andrianakis, I ;

Katsouyanni, K ;

Karmpaliotis, D ;

Economidou, J ;

Sfyras, D ;

Roussos, C .

CRITICAL CARE MEDICINE, 2000, 28 (01) :8-15

← 1 2 3 4 →